Disease-modifying antirheumatic drug

Summary of opinion: Bimzelx, 21/03/2024 Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Psoriatic arthritis, Hidradenitis suppurativa, Methotrexate, Psoriasis, MRI, Magnetic resonance imaging, Inflammation, Committee, Nonsteroidal anti-inflammatory drug, Disease-modifying antirheumatic drug, HS, Medication package insert, C-reactive protein, Ankylosing spondylitis, European Commission, Marketing, CHMP, CRP, Axial spondyloarthritis

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.
  • The marketing authorisation holder for this medicinal product is UCB Pharma S.A.
  • The CHMP adopted a new indication for the treatment of hidradenitis suppurativa.
  • Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
    Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Novotech Publishes Candidiasis and Rheumatoid Arthritis Clinical Trial Landscape Reports to Support Biotech Research Planning

Retrieved on: 
Monday, February 12, 2024
Therapy, Woman, Compound annual growth rate, Gene editing, Rheumatoid arthritis, APA, MicroRNA, Research, Investment, Molecular medicine, Candida albicans, Epidemiology, Geography, Death, Prevalence, Lead, Contract research organization, Joint, Organization, SWOT analysis, Optimism, Clinical trial, Diagnosis, Fungal infection, Disease-modifying antirheumatic drug, Pharmaceutical industry

The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.

Key Points: 
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.
  • These reports offer current insights into global clinical trial activity, revealing which regions experience the highest trial volumes and the factors behind these trends.
  • The Rheumatoid Arthritis (RA)– Global Clinical Trial Landscape report looks at the prevalence globally and identifies the key factors driving this condition.
  • Overall, this report provides vital insights into the global clinical trial landscape, detailing ongoing developments in RA research.

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Arava, European Commission, Arthritis, INN, Risk, ATC, Joint, Hepatotoxicity, DMARD, International, European, Disease, Language, Rheumatoid arthritis, Inflammation, Disease-modifying antirheumatic drug, Lymphocyte, Tablet, Select, Committee, Patient, Risk management, Anatomy, Medicine, Psoriatic arthritis, Methotrexate, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Contraindication, AZA, Axial spondyloarthritis, Rash, Tissue, ACR20, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Adolescence, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Nonsteroidal anti-inflammatory drug, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Select, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Child, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, TNF, INN, Immune system, Etanercept, Ulcerative colitis, Adolescence, Caregiver, PUVA, ATC, Joint, Crohn's disease, Psoriatic arthritis, Bleeding, International, Headache, Disease, Common, Ageing, Nose, Language, Arthritis, Inflammation, Hypersensitivity, Allergy, Disease-modifying antirheumatic drug, European Medicines Agency, Ulcer, Select, Anatomy, Methotrexate, IIA, DMARD, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 15/01/2009, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Global Musculoskeletal Disorders Drugs Market to Surge, Projected to Reach $109.4 Billion by 2029 with 4.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Pharmaceutical, Online, Osteoarthritis, Prevalence, Route of administration, Arena Pharmaceuticals, Arthritis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Analgesic, COVID-19, Distribution (marketing), Ageing, Microsoft, Bone, DSM-IV codes, MicroRNA, Life expectancy, Musculoskeletal disorder, Hospital, Arthropathy, Market, Administration, Back pain, Disease-modifying antirheumatic drug, Compound annual growth rate, UCB, Acquisition, AbbVie, Eli Lilly and Company, Pharmacy, Human musculoskeletal system, Growth, Johnson & Johnson, Immunology, Merck & Co., Novartis, Pharmaceutical industry, Agriculture, Pfizer

The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.

Key Points: 
  • The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
  • The rise in life expectancy and aging population leads to a surge in musculoskeletal diseases, boosting the demand for treatments and subsequently propelling market expansion.
  • High Prevalence of Musculoskeletal Diseases: Over 150 diseases and conditions fall under the category of musculoskeletal disorders, affecting individuals globally.
  • The prevalence of these disorders, such as arthritis, osteoarthritis, and back pain, drives the demand for drugs and treatment options.

Global Rheumatoid Arthritis Drugs Market Aims for $49.86 Billion by 2030: Addressing a Growing Autoimmune Challenge - ResearchAndMarkets.com

Retrieved on: 
Friday, September 8, 2023
Health, Pharmaceutical, Heart, Systematic review, Injection, Male, Telehealth, Connective tissue, Gland, TNF, Prevalence, Arthralgia, Arthritis, Ageing, Quality of life, Inflammation, Cell, Meta-analysis, CDC, Compound annual growth rate, Disease-modifying antirheumatic drug, Korea Disease Control and Prevention Agency, Rheumatoid arthritis, Immune system, Autoimmune disease, Joint, Eli Lilly and Company, Patient, Bacteria, PD-1, Safety, Virus, Skin, Disease, Pharmaceutical industry, Growth

The global Rheumatoid Arthritis Drugs Market is on track to achieve a significant milestone, projected to reach a value of US$ 49.86 billion by 2030.

Key Points: 
  • The global Rheumatoid Arthritis Drugs Market is on track to achieve a significant milestone, projected to reach a value of US$ 49.86 billion by 2030.
  • Key drivers of the global Rheumatoid Arthritis Drugs Market include the availability of high-cost medications, efficient reimbursement methods, rising prevalence rates, and regulatory standards.
  • North America is expected to continue holding a substantial market share in the treatment of rheumatoid arthritis.
  • The high prevalence of rheumatoid arthritis in the US, along with robust market players and innovative pharmaceutical research, drives market expansion.

Biologics and Targeted Therapies Revolutionize Psoriatic Arthritis Treatment: Market Analysis and Global Opportunity Assessment - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 2, 2023
Health, Other Health, Disease-modifying antirheumatic drug, Arthralgia, Psoriatic arthritis, Inflammation, Psoriasis, Route, Administration, Swelling, Nonsteroidal anti-inflammatory drug, OTC, Route of administration, Diagnosis, Skin, Geography, Pharmaceutical industry, Health insurance

The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psoriatic Arthritis Treatment Market by Drug Type, Type, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com's offering.
  • PsA is a chronic inflammatory arthritis that affects individuals with psoriasis, a skin condition characterized by red, scaly patches on the skin.
  • The psoriatic arthritis treatment market has witnessed growth due to increased awareness campaigns, educational initiatives, and advancements in diagnostic techniques, leading to early detection and diagnosis of PsA.
  • The psoriatic arthritis treatment market is segmented based on drug type, type, route of administration, and geography.